Lupin has announced that it will invest $250 million over 5 years to build a new 70,000 sq ft inhaler manufacturing facility in Coral Springs, Florida, USA, where the company opened an inhalation research center in 2015. Lupin also said that it expects to hire more than 200 skilled personnel for the new facility by 2030 and that the new plant will manufacture more than 25 respiratory products, including albuterol MDIs.
According to the company’s web site, Lupin currently has only one manufacturing facility in the US, an oral dosage form plant in New Jersey. In 2020, when the FDA approved Lupin’s generic version of Teva’s ProAir HFA albuterol MDI, the company said that it would manufacture the inhaler for the American market at one of its Indian facilities.
Lupin Chief Technical Operations Officer Christoph Funke commented, “The expansion of Lupin’s footprint in Coral Springs is a core part of our growth strategy. This new state-of-the-art facility will build on our existing presence in Florida, which is home to Lupin’s headquarters and our Advanced Inhalation Research Center. This investment demonstrates Lupin’s commitment to innovation, quality, and supply chain reliability and our ability to partner with Florida’s leaders to strengthen America’s medicine security by growing our capacity to produce affordable treatments for patients. We are grateful to Florida’s leadership for their partnership in making this possible.”
Read the Lupin press release
